Summit Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Conference
25 Novembre 2015 - 1:00PM
Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug
discovery and development company advancing therapies for Duchenne
muscular dystrophy and Clostridium difficile infection, announces
that Mr Glyn Edwards, Summit's Chief Executive Officer, will
present at the 27th Annual Piper Jaffray Healthcare Conference at
10:30am EST (3:30pm GMT) on Wednesday, 2 December 2015 in New York
City.
A live audio webcast of the presentation will be available
through the Investors section on the Company's website,
www.summitplc.com. A replay of the webcast will be available soon
after the live presentation.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for
indications for which there are no existing or only inadequate
therapies. Summit is conducting clinical programs focused on the
genetic disease DMD and the infectious disease Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter
(@summitplc).
For more information, please contact:
Summit |
|
Glyn Edwards / Richard Pye (UK office) |
Tel: +44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US
office) |
+1 617 225 4455 |
|
|
Cairn Financial Advisers
LLP |
|
(Nominated Adviser) |
|
Liam Murray / Tony Rawlinson |
Tel: +44 (0)20 77148 7900 |
|
|
N+1 Singer |
|
(Broker) |
|
Aubrey Powell / Jen Boorer |
Tel: +44 (0)20 7496 3000 |
|
|
Peckwater PR |
|
(Financial public relations, UK) |
Tel: +44 (0)7879 458 364 |
Tarquin Edwards |
tarquin.edwards@peckwaterpr.co.uk |
|
|
MacDougall Biomedical
Communications |
|
(US media contact) |
Tel: +1 781 235 3060 |
Chris Erdman |
cerdman@macbiocom.com |
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Août 2023 à Août 2024